Human Antibody ELISA (IgG)
COMING SOON
Determine AAV Antibodies in Human Sera
AAV Antibodies are known to be present in 20-90% of the human population, depending on the AAV serotype and population demographics, such as geographical location and age. Sero-positivity can have a major impact on the success of AAV-based gene therapies, as pre-existing antibodies can neutralize the AAV vector and trigger immune reactions, reducing treatment effectiveness and safety.
At PROGEN, we’ve developed easy-to-use AAV human antibody ELISAs (IgG) for multiple serotypes - serology assays designed to accurately detect antibodies against AAV in blood samples. These kits support the safety and gene therapy effectiveness by assessing pre-existing immunity before treatment and monitoring antibody levels during and after. Our AAV human antibody ELISAs also help streamline your workflow, by using standardized, commercially available tests, you can ensure consistent results across different studies. There's no need to develop a new assay for every gene therapy product - saving valuable time and simplifying the regulatory process.
The Principle
The assay is based on the ELISA technique. Serotype-specific AAV capsids are coated onto a microplate to capture antibodies from human serum samples binding fully assembled AAV particles of the corresponding serotype.
Captured AAV antibodies are detected in a two step process.
-
HRP-coupled anti-human IgG antibodies are bound to the AAV particle antibodies from the human serum sample.
-
After adding the substrate, the conjugated peroxidase catalyses the substrate reaction producing a bright colour. The absorbance is measured photometrically at 450nm and is relative to the concentration of specifically bound serum antibodies.
The Benefits
Easy-to-use
Ready-to-use kits including serotype-specific, anti-AAV antibody standards in six dilutions, as well as human positive and negative control sera.Convenient
No need for in-house assay development – multiple serotypes available – with more coming.Time-saving
Results within 2.5 hours, ideal for high-throughput environments, supporting automation.High-Quality
Backed by PROGEN´s extensive experience in the development of commercially available AAV ELISA kits and on our well-established quality control standards.Reliable
Extensive performance data available to support your validation process.What others are saying
'PROGEN's serology assays are user-friendly and offer a quick turnaround time. We can now efficiently analyze large numbers of patient samples with minimal effort in our lab, saving us time and resources without compromising on accuracy.'
Kirsten Coleman, Powell Gene Therapy Center, University of Florida
'Thanks to the AAV serology ELISA kits, we were able to rapidly analyse human sera for anti-AAV IgG levels to a range of capsid serotypes. The assay outputs aligned well with our results generated using traditional but laborious endpoint ELISAs indicating the kits potential in expediting epidemiological serological studies.'
Grant Logan, Children’s Hospital at Westmead & Children’s Medical Research Institute, Sydney, Australia
POSTER: AAV Serology ELISA for testing pre-existing Immunity to AAV
This poster takes a deep-dive into AAV serological ELISA kits. An easy-to use, straightforward solution for determining anti-AAV antibodies in patient serum, ensuring safety and efficacy in gene transfer by analyzing preexisting immunity before, during and after treatment.
